ArticleJournal of the American Heart Association2025
Metabolic Vulnerability Index and Atherosclerosis Incident: A Prospective Cohort Study From the UK Biobank.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic vulnerability index and MetaboHealth score as risk factors for age-related macular degeneration in a large-scale prospective cohort.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerosis underlies most cardiovascular disease, but traditional factors incompletely explain risk. This study examined whether a novel Metabolic Vulnerability Index (MVX), integrating inflammatory and metabolic biomarkers, predicts incident atherosclerosis independently of traditional and genetic risks.
methodsWe analyzed data from 171 600 participants in the UK Biobank without baseline atherosclerotic disease (median follow-up, 13.6 years). MVX was derived from nuclear magnetic resonance metabolomics and comprised 2 components: the Inflammatory Vulnerability Index (including glycoprotein acetyls and small high-density lipoprotein particle concentration) and the Metabolic Malnutrition Index (including branched-chain amino acids and citrate). Associations with incident atherosclerosis (ascertained via hospitalizations and death) were analyzed using Cox models adjusted for demographics and clinical and lifestyle factors. Secondary analyses evaluated MVX components independently and examined potential effect modification by genetic risk using low-density lipoprotein cholesterol polygenic risk scores.
resultsHigher MVX predicted significantly increased atherosclerosis risk (hazard ratio [HR] per SD: 1.22 [95% CI, 1.19-1.25]). The highest MVX quartile had 59% greater risk compared with the lowest (HR, 1.59 [95% CI, 1.49-1.69]). This association persisted after adjustment for traditional cardiovascular risk factors. The Inflammatory Vulnerability Index demonstrated robust positive associations with atherosclerosis (adjusted HR per SD, 1.18 [95% CI, 1.15-1.21]). MVX-atherosclerosis associations remained consistent across different genetic risk strata and demographic subgroups.
conclusionsThe MVX, particularly its inflammatory component, independently predicts atherosclerosis risk beyond traditional risk factors. This supports comprehensive metabolic profiling for refined risk assessment and underscores inflammation's central role in atherosclerosis progression, highlighting potential novel intervention targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.